Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma

Lymphoma

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

Lung Cancer.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I

doi: 10.1016/

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

Lung Cancer.

Hsu KH, Huang YH, Tseng JS, Chen KC, Ku WH, Su KY, Chen JJW, Chen HW, Yu SL, Yang TY, Chang GC

doi: 10.1016/j.lungcan.2018.11.021.

Lung, Respiratory and Thoracic Cancer

Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma

J Thorac Oncol.

Yu H, Chen Z, Ballman K, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac L, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky K, Harpole D, Joshi M, Merrick DT, Richards W, Rivard CJ, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR

doi: 10.1016/j.jtho.2018.09.006.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lung, Respiratory and Thoracic Cancer

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Ann Oncol.

Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R, Sawan P, Beras A, Egger JV, Ladanyi M, Arbour KC, Rudin CM, Riely GJ, Taylor BS, Donoghue MTA, Hellmann MD

doi: 10.1016/j.annonc.2020.01.065.

Lung, Respiratory and Thoracic CancerLymphoma

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer

J Thorac Oncol.

Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT

doi: 10.1016/j.jtho.2017.01.004.

Lung, Respiratory and Thoracic Cancer

Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer

Ann Oncol.

Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM

doi: 10.1016/j.annonc.2020.02.017.

Lung, Respiratory and Thoracic Cancer

Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers

J Thorac Oncol.

Sato H, Offin M, Kubota D, Yu HA, Wilhelm C, Toyooka S, Somwar R, Kris MG, Ladanyi M

doi: 10.1016/j.jtho.2020.09.019.

Lung, Respiratory and Thoracic Cancer

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50

Ann Oncol.

Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD

doi: 10.1016/j.annonc.2019.11.015.

Related content

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer

Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer

Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50